Evidence map›Paper›PMID 28029115›Full record

ArticleInternational journal of molecular sciences2016

Development of Orally Administered γ-Tocotrienol (GT3) Nanoemulsion for Radioprotection.

Grace A Ledet, Shukla Biswas, Vidya P Kumar, Richard A Graves, Demaurian M Mitchner, Taylor M Parker, Levon A Bostanian, Sanchita P Ghosh, Tarun K Mandal

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Natural Guardians: Natural Compounds as Radioprotectors in Cancer Therapy.International journal of molecular sciences · 2024
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Grace A LedetCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. grace.ledet@gmail.com.
Shukla BiswasArmed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. shukla.biswas.ctr@usuhs.edu.
Vidya P KumarArmed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. vidya.kumar.ctr@usuhs.edu.
Richard A GravesCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. rgraves@xula.edu.
Demaurian M MitchnerCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. dmitchne@xula.edu.
Taylor M ParkerCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. tparker4@xula.edu.
Levon A BostanianCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. lbostani@xula.edu.
Sanchita P GhoshArmed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. sanchita.ghosh@usuhs.edu.
Tarun K MandalCenter for Nanomedicine & Drug Delivery, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA. tmandal@xula.edu.

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
NIMHD NIH HHS G12 MD007595
6 · The paper itself

Abstract

The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound. γ-tocotrienol was incorporated into a nanoemulsion and lyophilized with lactose. Ultra performance liquid chromatography-mass spectroscopy (UPLC-MS) was used to monitor the chemical stability of GT3 over time, the particle size and ζ potential, and scanning electron microscopy (SEM) were used to study the physical stability of the nanoemulsion. Radioprotective and toxicity studies were performed in mice. The liquid formulation exhibited GT3 degradation at all storage temperatures. Lyophilization, in the presence of lactose, significantly reduced GT3 degradation. Both the liquid and lyophilized nanoemulsions had stable particle size and ζ potential when stored at 4 °C. Toxicity studies of the nanoemulsion resulted in no observable toxicity in mice at an oral dose of 600 mg/kg GT3. The nano-formulated GT3 (300 mg/kg) demonstrated enhanced survival efficacy compared to GT3 alone (200 and 400 mg/kg) in CD2F1 mice exposed to total body gamma radiation. The optimal long-term storage of formulated GT3 is as a powder at -20 °C to preserve drug and formulation integrity. Formulation of GT3 as a nanoemulsion for oral delivery as a prophylactic radioprotectant shows promise and warrants further investigation.

Indexed as

Acute Radiation SyndromeAdministration, OralAnimalsChromansDrug StabilityEmulsionsLactoseMaleMiceRadiation-Protective AgentsVitamin EChromansEmulsionsLactoseplastochromanol 8Radiation-Protective AgentsVitamin Edry emulsionGT3lyophilizationnanoemulsionradioprotectionγ-tocotrienol

Identifiers

PMID28029115
PMCPMC5297663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.